This represents a strategic investment in state-of-the-art technology and medical innovation, marking an important step toward the automation of laboratory processes.
The MedLife PDR Laboratory in Brasov has been equipped with a fully automated AbbottGLP line, integrating the most advanced robotic modules for sorting, loading-unloading, centrifuging, sampling, and storing samples, as well as high-capacity biochemistry and immunology analyzers – Alinity. Additionally, the laboratory has been outfitted with a Sysmex automated hematology line, complemented by a system for preparing and staining blood smears. The entire robotic system is supported by Artificial Intelligence and middleware software, which manages the workflow, controls the modules, and validates the results. This advanced technological infrastructure enables rigorous process standardization and helps eliminate human errors in the interpretation of laboratory data, the report shows.
“Laboratory automation is one of the strategic directions through which MedLife aims to address the challenges of modern medicine: the need for speed, precision, and operational efficiency. In recent years, we have accelerated investments in advanced technologies for our diagnostic network, and the fully automated laboratory in Brasov perfectly reflects this vision. It is an essential step to increase processing capacity at the regional level, as well as to bring innovation closer to patients. Brasov thus becomes a key pillar in our laboratory network, a regional hub serving not only the county but also surrounding areas, offering fast, reliable, and standardized diagnostic services. We believe in predictable laboratory medicine, supported by technology,” said Dorin Preda, Deputy CEO MedLife Group.
According to the report, “MedLife PDR Brasov Laboratory is the second largest in the MedLife Group, after the central laboratory in Bucharest, and the second to integrate an automated laboratory line. Covering an area of approximately 700 square meters, it serves 25 collection points in the counties of Brasov, Covasna, and Mures, functioning as a regional processing hub for samples and a national center for highly specialized tests, such as myelograms. Aligned with MedLife’s strategy to support precision medicine, one of the laboratory’s major objectives is the development of a highly specialized testing center in oncohematology, which will offer oncology patients access to a complete care pathway – from diagnosis to treatment and monitoring.”
MedLife PDR Brasov, founded in 1994, has processed approximately 15 million tests over time through its own laboratory, becoming a benchmark in medical analysis in the region. With this new investment in automation and cutting-edge technology, the laboratory strengthens its position as a regional leader in diagnostic services, contributing to improving the quality of medical care for hundreds of thousands of patients
MedLife ended the first quarter of 2025 with consolidated pro forma turnover of RON779 million, 20% higher than the year-earlier level, and net profit of RON10 million, down 19% year-over-year.
MedLife has a market capitalization of RON3.6 billion. Its biggest shareholders are Mihail Marcu, with a 14.38% stake, Mihaela Gabriela Cristescu, with 14.04%, Fondul de Pensii Administrat Privat NN, with 13.23%, and Nicolae Marcu, with 10.27%.